ALLURION TECHNOLOGIES, INC.
Company Information
Industry Surgical & Medical Instruments & Apparatus
SIC Code 3841
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation DE
Business Address 11 HURON DR STE 200, NATICK, MA, 01760
Mailing Address 11 HURON DR STE 200, NATICK, MA, 01760
Phone 508-647-4000
Fiscal Year End 1231
EIN 000000000
Financial Overview
FY2025
$32.81M
Total Assets
$15.38M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 30, 2026 | View on SEC |
| 8-K Current report of material events | March 12, 2026 | View on SEC |
| 8-K Current report of material events | March 2, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | March 2, 2026 | View on SEC |
| 8-K Current report of material events | February 25, 2026 | View on SEC |
| 8-K Current report of material events | February 23, 2026 | View on SEC |
| 5 Annual insider ownership changes | February 17, 2026 | View on SEC |
| 5 Annual insider ownership changes | February 17, 2026 | View on SEC |
| 8-K Current report of material events | January 12, 2026 | View on SEC |
| S-3 Shelf registration for future offerings | January 9, 2026 | View on SEC |
Annual Reports
10-K March 30, 2026
- FDA approval received in February 2026 for the U.S. market, the world's largest weight-loss sector.
- Revenue grew 12% to $65.2 million, driven by strong international performance.
Material Events
8-K Financial Distress March 12, 2026
High Impact
- Allurion recently received FDA approval for its Allurion Gastric Balloon System (featuring the Allurion Smart Capsule) in the U.S. in September 2023.
- The company has a detailed strategic plan to accelerate its U.S. commercial launch, improve operational efficiency, and explore strategic financing options to strengthen its financial position.
8-K Financial Distress March 2, 2026
High Impact
- Allurion Technologies is actively appealing the NYSE delisting notice.
- The company is pursuing financial restructuring efforts, including a debt-for-preferred stock swap and a warrant inducement transaction.
8-K Other December 19, 2025
High Impact
- Allurion Technologies held its 2025 Annual Meeting of Stockholders where shareholders voted on several key proposals.
- Shareholders approved an updated employee stock incentive plan, making more shares available for employee incentives.
Insider Trading
SELL 1 insiders
2 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 3841)
Picard Medical, Inc.
PMI Surgical & Medical Instruments & Apparatus
Neuronetics, Inc.
STIM Surgical & Medical Instruments & Apparatus
Nuo Therapeutics, Inc.
AURX Surgical & Medical Instruments & Apparatus
Cytosorbents Corp
CTSO Surgical & Medical Instruments & Apparatus
QHSLab, Inc.
USAQ Surgical & Medical Instruments & Apparatus
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.